Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2017 Filed Mar 10, 2017 17:22 UTC |
Michael Robert A.VP, Controller
|
SaleCommon stock, $0.01 par value | 5,132 | $65.29 | $335,068.28 |
DisclosureSEC source: 0001179110-17-004442 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,706 Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 17:20 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 53,650 | $0.00 Strike: $29.23 | $0.00 |
DisclosureSEC source: 0001179110-17-004436 · edgar.xml · derivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 53,650 shares Expires 2022-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 17:20 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 18,366 | $0.00 Strike: $24.21 | $0.00 |
DisclosureSEC source: 0001179110-17-004436 · edgar.xml · derivative · entry 7 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 18,366 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 17:20 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 72,016 | $64.25 | $4,627,028.00 |
DisclosureSEC source: 0001179110-17-004436 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,747 Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 17:20 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionCommon stock, $0.01 par value | 53,650 | $29.23 | $1,568,001.73 |
DisclosureSEC source: 0001179110-17-004436 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 17:20 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionCommon stock, $0.01 par value | 18,366 | $24.21 | $444,607.80 |
DisclosureSEC source: 0001179110-17-004436 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:10 UTC |
ALBAN CARLOSEVP, Commercial Operations
|
Tax withholdingCommon stock, $0.01 par value | 34,721 | $62.22 | $2,160,340.62 |
DisclosureSEC source: 0001179110-17-003699 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,745 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:11 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
Tax withholdingCommon stock, $0.01 par value | 40,212 | $62.22 | $2,501,990.64 |
DisclosureSEC source: 0001179110-17-003700 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,543 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 18:11 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Tax withholdingCommon stock, $0.01 par value | 112,867 | $62.22 | $7,022,584.74 |
DisclosureSEC source: 0001179110-17-003701 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,747 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:12 UTC |
Gosebruch Henry OChief Strategy Officer
|
Tax withholdingCommon stock, $0.01 par value | 20,673 | $62.22 | $1,286,274.06 |
DisclosureSEC source: 0001179110-17-003702 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,737 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:12 UTC |
HURWICH THOMAS A.VP, Controller
|
Tax withholdingCommon stock, $0.01 par value | 4,947 | $62.22 | $307,802.34 |
DisclosureSEC source: 0001179110-17-003703 · edgar.xml · nonDerivative · entry 4 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,329 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:12 UTC |
HURWICH THOMAS A.VP, Controller
|
SaleCommon stock, $0.01 par value | 200 | $61.90 | $12,379.00 |
DisclosureSEC source: 0001179110-17-003703 · edgar.xml · nonDerivative · entry 3 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,276 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:12 UTC |
HURWICH THOMAS A.VP, Controller
|
SaleCommon stock, $0.01 par value | 1,911 | $61.89 | $118,273.70 |
DisclosureSEC source: 0001179110-17-003703 · edgar.xml · nonDerivative · entry 2 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,476 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:12 UTC |
HURWICH THOMAS A.VP, Controller
|
SaleCommon stock, $0.01 par value | 200 | $61.89 | $12,378.00 |
DisclosureSEC source: 0001179110-17-003703 · edgar.xml · nonDerivative · entry 1 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,387 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:13 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
Tax withholdingCommon stock, $0.01 par value | 18,902 | $62.22 | $1,176,082.44 |
DisclosureSEC source: 0001179110-17-003704 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,529 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:13 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
Tax withholdingCommon stock, $0.01 par value | 19,096 | $62.22 | $1,188,153.12 |
DisclosureSEC source: 0001179110-17-003705 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,299 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:14 UTC |
Schumacher Laura JExecutive Vice President
|
Tax withholdingCommon stock, $0.01 par value | 35,583 | $62.22 | $2,213,974.26 |
DisclosureSEC source: 0001179110-17-003706 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,825 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:14 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
Tax withholdingCommon stock, $0.01 par value | 30,699 | $62.22 | $1,910,091.78 |
DisclosureSEC source: 0001179110-17-003707 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,131 Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC |
ALBAN CARLOSEVP, Commercial Operations
|
GrantOption (right to buy) · Derivative | 95,750 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002804 · edgar.xml · derivative · entry 4 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,750 Underlying: Common stock · 95,750 shares Expires 2027-02-15 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 31,917 on 02/16/2018, 31,916 on 02/16/2019, and 31,917 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC |
ALBAN CARLOSEVP, Commercial Operations
|
GrantCommon stock, $0.01 par value | 13,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002804 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,466 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC |
ALBAN CARLOSEVP, Commercial Operations
|
GrantCommon stock, $0.01 par value | 29,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002804 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,116 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
GrantOption (right to buy) · Derivative | 100,100 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002805 · edgar.xml · derivative · entry 4 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,100 Underlying: Common stock · 100,100 shares Expires 2027-02-15 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 33,367 on 02/16/2018, 33,366 on 02/16/2019, and 33,367 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
GrantCommon stock, $0.01 par value | 15,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002805 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,755 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
GrantCommon stock, $0.01 par value | 35,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002805 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,810 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:51 UTC |
Gosebruch Henry OChief Strategy Officer
|
GrantOption (right to buy) · Derivative | 78,340 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002807 · edgar.xml · derivative · entry 4 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,340 Underlying: Common stock · 78,340 shares Expires 2027-02-15 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 26,114 on 02/16/2018, 26,113 on 02/16/2019, and 26,113 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:51 UTC |
Gosebruch Henry OChief Strategy Officer
|
GrantCommon stock, $0.01 par value | 14,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002807 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,410 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:51 UTC |
Gosebruch Henry OChief Strategy Officer
|
GrantCommon stock, $0.01 par value | 31,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002807 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,375 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 17:51 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantOption (right to buy) · Derivative | 261,150 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002808 · edgar.xml · derivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,150 Underlying: Common stock · 261,150 shares Expires 2027-02-15 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 87,050 on 02/16/2018, 87,050 on 02/16/2019, and 87,050 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 17:51 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon stock, $0.01 par value | 42,651 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002808 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,614 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 17:51 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon stock, $0.01 par value | 94,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002808 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,963 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:51 UTC |
HURWICH THOMAS A.VP, Controller
|
GrantOption (right to buy) · Derivative | 13,050 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002810 · edgar.xml · derivative · entry 5 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,050 Underlying: Common shares · 13,050 shares Expires 2027-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 4,350 on 02/16/2018, 4,350 on 02/16/2019, and 4,350 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:51 UTC |
HURWICH THOMAS A.VP, Controller
|
GrantCommon stock, $0.01 par value | 2,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002810 · edgar.xml · nonDerivative · entry 2 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,587 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:51 UTC |
HURWICH THOMAS A.VP, Controller
|
GrantCommon stock, $0.01 par value | 5,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002810 · edgar.xml · nonDerivative · entry 1 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,061 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:52 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
GrantOption (right to buy) · Derivative | 45,700 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002811 · edgar.xml · derivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,700 Underlying: Common stock · 45,700 shares Expires 2027-02-15 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 15,234 on 02/16/2018, 15,233 on 02/16/2019, and 15,233 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:52 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
GrantCommon stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002811 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,431 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:52 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
GrantCommon stock, $0.01 par value | 15,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002811 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,351 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:52 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
GrantOption (right to buy) · Derivative | 47,870 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002813 · edgar.xml · derivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,870 Underlying: Common stock · 47,870 shares Expires 2027-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 15,957 on 02/16/2018, 15,956 on 02/16/2019, and 15,957 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:52 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
GrantCommon stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002813 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,395 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:52 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
GrantCommon stock, $0.01 par value | 15,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002813 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,315 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:53 UTC |
Schumacher Laura JExecutive Vice President
|
GrantOption (right to buy) · Derivative | 100,100 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002814 · edgar.xml · derivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,100 Underlying: Common stock · 100,100 shares Expires 2027-02-15 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 33,367 on 02/16/2018, 33,366 on 02/16/2019, and 33,367 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:53 UTC |
Schumacher Laura JExecutive Vice President
|
GrantCommon stock, $0.01 par value | 13,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002814 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,408 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:53 UTC |
Schumacher Laura JExecutive Vice President
|
GrantCommon stock, $0.01 par value | 29,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002814 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,298 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:53 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
GrantOption (right to buy) · Derivative | 100,100 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002816 · edgar.xml · derivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,100 Underlying: Common stock · 100,100 shares Expires 2027-02-15 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 33,367 on 02/16/2018, 33,366 on 02/16/2019, and 33,367 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:53 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
GrantCommon stock, $0.01 par value | 15,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002816 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,830 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:53 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
GrantCommon stock, $0.01 par value | 34,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002816 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,455 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 17:17 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GiftCommon Stock, $0.01 par value | 8,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001673 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,166 Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 22:21 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
Exercise / conversionOption (right to buy) · Derivative | 2,400 | $0.00 Strike: $27.29 | $0.00 |
DisclosureSEC source: 0001179110-17-001675 · edgar.xml · derivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common stock · 2,400 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 22:21 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
Tax withholdingCommon stock, $0.01 par value | 1,558 | $60.89 | $94,866.62 |
DisclosureSEC source: 0001179110-17-001675 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 3,873 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by her spouse. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 22:21 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
Exercise / conversionCommon stock, $0.01 par value | 2,400 | $27.29 | $65,496.00 |
DisclosureSEC source: 0001179110-17-001675 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 5,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by her spouse. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 22:31 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 104 | $62.62 Strike: $0.00 | $6,512.48 |
DisclosureSEC source: 0001179110-17-000295 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,194 Underlying: Common Stock · 104 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.